Deutsche Bank AG Has $21.45 Million Stake in Vera Therapeutics, Inc. $VERA

Key Points

• Deutsche Bank AG increased its holdings in Vera Therapeutics by 10.2%, acquiring an additional 82,483 shares to hold a total of 892,859 shares valued at approximately $21.4 million.
• Vera Therapeutics reported a net loss of ($1.20) EPS for the latest quarter, significantly missing analyst estimates, while the consensus rating on the stock remains a Moderate Buy with a price target of $63.00.
• Institutional investors own 99.21% of Vera Therapeutics stock, reflecting strong confidence from major financial backers in the company’s potential in developing treatments for serious immunological diseases.

Deutsche Bank AG increased its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 10.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 892,859 shares of the company's stock after purchasing an additional 82,483 shares during the period. Deutsche Bank AG owned 1.40% of Vera Therapeutics worth $21,446,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Avoro Capital Advisors LLC lifted its stake in shares of Vera Therapeutics by 30.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock worth $237,247,000 after acquiring an additional 1,300,410 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Vera Therapeutics by 11.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company's stock worth $185,107,000 after acquiring an additional 437,940 shares during the period. Paradigm Biocapital Advisors LP lifted its stake in shares of Vera Therapeutics by 31.0% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company's stock worth $60,785,000 after acquiring an additional 340,488 shares during the period. T. Rowe Price Investment Management Inc. lifted its stake in shares of Vera Therapeutics by 43.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,415,179 shares of the company's stock worth $59,848,000 after acquiring an additional 431,178 shares during the period. Finally, First Light Asset Management LLC lifted its stake in shares of Vera Therapeutics by 78.8% in the 4th quarter. First Light Asset Management LLC now owns 1,261,246 shares of the company's stock worth $53,338,000 after acquiring an additional 556,012 shares during the period. Institutional investors and hedge funds own 99.21% of the company's stock.

Insider Activity

In other news, Director Patrick G. Enright purchased 209,393 shares of Vera Therapeutics stock in a transaction dated Monday, June 23rd. The stock was bought at an average price of $20.87 per share, with a total value of $4,370,031.91. Following the completion of the acquisition, the director owned 3,569,522 shares in the company, valued at $74,495,924.14. The trade was a 6.23% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 16.30% of the company's stock.

Vera Therapeutics Stock Up 0.6%

Shares of NASDAQ:VERA traded up $0.12 during midday trading on Monday, reaching $21.66. The company had a trading volume of 541,182 shares, compared to its average volume of 1,296,674. The company has a debt-to-equity ratio of 0.16, a current ratio of 17.03 and a quick ratio of 17.03. The stock's fifty day moving average price is $22.13 and its 200-day moving average price is $24.50. The stock has a market capitalization of $1.38 billion, a P/E ratio of -6.01 and a beta of 1.17. Vera Therapeutics, Inc. has a one year low of $18.53 and a one year high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.38). During the same quarter in the previous year, the company posted ($0.62) EPS. Equities research analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

VERA has been the subject of several recent analyst reports. Scotiabank restated an "outperform" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. HC Wainwright restated a "buy" rating and set a $85.00 target price (up from $75.00) on shares of Vera Therapeutics in a report on Monday, June 2nd. Wolfe Research reiterated a "peer perform" rating on shares of Vera Therapeutics in a report on Monday, August 4th. Guggenheim reissued a "buy" rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. Finally, Wedbush reduced their price target on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Vera Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $63.00.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.